When you get a diagnosis of multiple myeloma, you may not even know what it is. Find out why this type of cancer is different from most others and what your treatment options look like.

One of the complications of multiple myeloma is the development of lytic bone lesions. Learn about the causes, symptoms and management of bone lesions associated with multiple myeloma at WebMD.

By contrast, SMM progresses to active multiple myeloma at a rate of 10% per year in the first 5 years after diagnosis. After 15 years, the cumulative risk of progression from SMM to active ...

We diagnose multiple myeloma by doing blood, urine, bone marrow, and imaging tests. The disease can be classified as being “smoldering myeloma,” which is typically closely monitored, and “active ...

TRiMM-2: Response Rate of 78% Seen in Patients Who Receive Talquetamab With Subcutaneous Daratumumab for Multiple Myeloma. Updated results from the phase 2 TRiMM-2 study (NCT04108195) reported ...

The timing with which patients with newly diagnosed multiple myeloma began treatment with oral antimyeloma medications varied greatly by age and race, according to retrospective study results ...

Potential reasons for delayed treatment initiation of guideline-directed oral medications to treat multiple myeloma (MM), and that demonstrate significant disparities to work at overcoming ...

Opna Bio Presents Promising Preclinical Data in Multiple Myeloma with OPN-6602 and in Malignant Mesothelioma with OPN ... a dual EP300/CBP inhibitor in multiple myeloma, and OPN-9840, an oral, ...

Non-vitamin k oral antagonists versus aspirin for primary thromboprophylaxis in patients with multiple myeloma on outpatient chemotherapy: A systematic review and meta-analysis. Bruno Almeida Costa , ...